Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Profit After Tax (2021 - 2025)

Historic Profit After Tax for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $18.4 million.

  • Kiniksa Pharmaceuticals International's Profit After Tax rose 24523.75% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.9 million, marking a year-over-year increase of 49609.62%. This contributed to the annual value of -$43.2 million for FY2024, which is 40668.13% down from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported Profit After Tax of $18.4 million as of Q3 2025, which was up 24523.75% from $17.8 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's 5-year Profit After Tax high stood at $224.1 million for Q3 2022, and its period low was -$49.5 million during Q1 2021.
  • Its 5-year average for Profit After Tax is $2.2 million, with a median of -$12.3 million in 2023.
  • Its Profit After Tax has fluctuated over the past 5 years, first surged by 83367.27% in 2022, then plummeted by 13521.81% in 2024.
  • Kiniksa Pharmaceuticals International's Profit After Tax (Quarter) stood at -$36.3 million in 2021, then skyrocketed by 112.28% to $4.5 million in 2022, then soared by 465.73% to $25.2 million in 2023, then tumbled by 135.22% to -$8.9 million in 2024, then surged by 307.41% to $18.4 million in 2025.
  • Its Profit After Tax stands at $18.4 million for Q3 2025, versus $17.8 million for Q2 2025 and $8.5 million for Q1 2025.